{"id":51835,"date":"2022-12-12T07:02:08","date_gmt":"2022-12-12T06:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/"},"modified":"2022-12-12T07:02:08","modified_gmt":"2022-12-12T06:02:08","slug":"clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/","title":{"rendered":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286"},"content":{"rendered":"
\n

\nReceives Commitment for up to $75 Million in Debtor-in-Possession Financing<\/i>\n<\/p>\n

BOULDER, Colo.–(BUSINESS WIRE)–$CLVS<\/a>–Clovis Oncology, Inc. (NASDAQ:CLVS) (\u201cClovis\u201d or the Company\u201d), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the \u201cDebtors\u201d) have voluntarily initiated a Chapter 11 proceeding in the United States Bankruptcy Court for the District of Delaware (\u201cBankruptcy Court\u201d) and will seek to sell their assets through a court supervised sales process.\n<\/p>\n

<\/a><\/p>\n

\nThe Debtors have filed various \u201cfirst day\u201d motions with the Bankruptcy Court requesting customary relief that will enable them to transition into Chapter 11 without material disruption to their ordinary course operations, including seeking authority to obtain debtor-in-possession (\u201cDIP\u201d) financing and pay employee wages and benefits.\n<\/p>\n

\nDIP Financing<\/span><\/b>\n<\/p>\n

\nIn order to provide necessary funding during the Chapter 11 proceeding, Clovis has received a commitment of up to $75 million in a multi-draw DIP financing facility. Upon approval by the Bankruptcy Court, the DIP financing is expected to provide Clovis with the necessary liquidity to operate in the normal course and meet obligations to its employees, vendors and customers throughout the Chapter 11 proceeding while executing on the sales process.\n<\/p>\n

\nSales Process<\/span><\/b>\n<\/p>\n

\nPrior to the Chapter 11 filing, and subject to Bankruptcy Court approval, the Company entered into a \u201cstalking horse\u201d purchase and assignment agreement with Novartis Innovative Therapies AG (\u201cNovartis\u201d) to acquire substantially all of the rights of the Company to its pipeline clinical candidate, FAP-2286, as a therapeutic agent for an upfront payment of $50 million and up to an additional $333.75 million upon the successful achievement of specified development and regulatory milestones and $297 million in later sales milestones. The transaction is part of a sale process under Section 363 of the Bankruptcy Code that will be subject to compliance with agreed upon and Bankruptcy Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions. In addition, the transaction is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. In accordance with the sale process under Section 363 of the Bankruptcy Code, notice of the proposed sale to Novartis will be given to third parties and competing bids will be solicited. The Company will manage the bidding process and evaluate any bids received, in consultation with its advisors and as overseen by the Bankruptcy Court.\n<\/p>\n

\nClovis is also actively engaged in discussions with a number of interested parties with respect to a potential sale of one or more of its other assets. Any of those sales would be subject to review and approval by the Bankruptcy Court and compliance with Bankruptcy Court-approved bidding procedures.\n<\/p>\n

\nClovis is represented by Willkie Farr & Gallagher LLP as counsel, AlixPartners LLP as restructuring advisor and Perella Weinberg Partners L.P. as restructuring investment banker.\n<\/p>\n

\nAdditional information about the Chapter 11 case, including access to Bankruptcy Court documents, is available online at https:\/\/cases.ra.kroll.com\/Clovis<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release includes statements that are, or may be deemed, \u201cforward-looking statements.\u201d In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the terms \u201cbelieves,\u201d \u201cestimates,\u201d \u201canticipates,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201capproximately\u201d or, in each case, their negative or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. <\/i>These forward-looking statements reflect the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained herein. <\/i>Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. Clovis\u2019 forward-looking statements in this press release include, but are not limited to, statements about Clovis\u2019 plans to sell its assets pursuant to Chapter 11 of the U.S. Bankruptcy Code and the timing of such sales and ability to satisfy closing conditions\u037e Clovis\u2019 intention to continue operations during the Chapter 11 case\u037e Clovis\u2019 belief that the sale process will be in the best interest of Clovis and its stakeholders\u037e and other statements regarding Clovis\u2019 strategy and future operations, performance and prospects, among others. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Clovis will be those anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Clovis\u2019 control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks associated with the potential adverse impact of the Chapter 11 filings on Clovis\u2019 liquidity and results of operations\u037e changes in Clovis\u2019 ability to meet its financial obligations during the Chapter 11 process and to maintain contracts that are critical to its operations\u037e the outcome and timing of the Chapter 11 process and any potential asset sale\u037e the effect of the Chapter 11 filings and any potential asset sale on Clovis\u2019 relationships with vendors, regulatory authorities, employees and other third parties\u037e possible proceedings that may be brought by third parties in connection with the Chapter 11 process or the potential asset sale\u037e uncertainty regarding obtaining Bankruptcy Court of a sale of Clovis\u2019 assets or other conditions to the potential asset sale\u037e and the timing or amount of any distributions, if any, to Clovis\u2019 stakeholders.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nClovis Contacts:<\/b>
investorinquiries@clovisoncology.com<\/a>
clovismedia@clovisoncology.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Receives Commitment for up to $75 Million in Debtor-in-Possession Financing BOULDER, Colo.–(BUSINESS WIRE)–$CLVS–Clovis Oncology, Inc. (NASDAQ:CLVS) (\u201cClovis\u201d or the Company\u201d), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the \u201cDebtors\u201d) have voluntarily initiated … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51835","6":"format-standard","7":"category-industry"},"yoast_head":"\nClovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Receives Commitment for up to $75 Million in Debtor-in-Possession Financing BOULDER, Colo.–(BUSINESS WIRE)–$CLVS–Clovis Oncology, Inc. (NASDAQ:CLVS) (\u201cClovis\u201d or the Company\u201d), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the \u201cDebtors\u201d) have voluntarily initiated ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-12T06:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221211005087\/en\/305545\/21\/Clovis_Logo_Process_Color.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286\",\"datePublished\":\"2022-12-12T06:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/\"},\"wordCount\":998,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221211005087\\\/en\\\/305545\\\/21\\\/Clovis_Logo_Process_Color.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/\",\"name\":\"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221211005087\\\/en\\\/305545\\\/21\\\/Clovis_Logo_Process_Color.jpg\",\"datePublished\":\"2022-12-12T06:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221211005087\\\/en\\\/305545\\\/21\\\/Clovis_Logo_Process_Color.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221211005087\\\/en\\\/305545\\\/21\\\/Clovis_Logo_Process_Color.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/","og_locale":"en_US","og_type":"article","og_title":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Pharma Trend","og_description":"Receives Commitment for up to $75 Million in Debtor-in-Possession Financing BOULDER, Colo.–(BUSINESS WIRE)–$CLVS–Clovis Oncology, Inc. (NASDAQ:CLVS) (\u201cClovis\u201d or the Company\u201d), a biopharmaceutical company focused on acquiring, developing, and commercializing innovative anti-cancer agents in the U.S., Europe, and additional international markets, today announced that it and certain of its subsidiaries (collectively, the \u201cDebtors\u201d) have voluntarily initiated ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-12T06:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221211005087\/en\/305545\/21\/Clovis_Logo_Process_Color.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286","datePublished":"2022-12-12T06:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/"},"wordCount":998,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221211005087\/en\/305545\/21\/Clovis_Logo_Process_Color.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/","url":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/","name":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221211005087\/en\/305545\/21\/Clovis_Logo_Process_Color.jpg","datePublished":"2022-12-12T06:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221211005087\/en\/305545\/21\/Clovis_Logo_Process_Color.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221211005087\/en\/305545\/21\/Clovis_Logo_Process_Color.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/clovis-oncology-files-for-chapter-11-protection-and-enters-into-agreement-to-sell-fap-2286\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51835"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51835\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}